| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President & CEO, Usstc
1 company
Brian W. Quigley last filed a Form 4 in April 2020, as President & CEO, Usstc at MO. Brian W. Quigley's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 20,702 shares of MO. The MO filings lean toward selling, a net 6,464 shares.
Brian W. Quigley has 13 Form 4 filings on record from January 2015 to April 2020, across 2 companies: Director at Lexaria Bioscience (LEXX), 2019–2020; President & CEO, Usstc at Altria Group (MO), 2015–2018.
The 13 reported transactions were 4 tax withholdings, 4 stock awards, 2 option or other derivative awards and 2 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $407K.
The largest open-market sale was 3,464 shares of MO at an average $62.40 on March 2, 2018, about $216K.
Shares as reported in the last Form 4 for each company; the most recent is from April 2020. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.